Drugs & Targets FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer January 09, 2026Vol.52 No.1
Cancer Policy Angelo de Claro named acting director of FDA Oncology Center of Excellence December 19, 2025Vol.51 No.46By Jacquelyn Cobb
Drugs & Targets FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer December 19, 2025Vol.51 No.46
Drugs & Targets FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma December 19, 2025Vol.51 No.46
Drugs & Targets FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results December 19, 2025Vol.51 No.46
Podcast Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it? December 17, 2025
Regulatory News FDA withdraws proposed rule for asbestos testing in talc-based cosmeticsIt’s anyone’s guess whether the agency is preparing to strengthen or relax talc regulation December 12, 2025Vol.51 No.45By Claire Marie Porter
Cancer Policy Former FDA Commissioner Scott Gottlieb speaks out against CDC vaccine panel December 12, 2025Vol.51 No.45By Sara Willa Ernst
